Skip to content

The effect of using abdominal binder on clinical outcomes of cesarean section

Comparison of the effects using abdominal binder and routine medical care on clinical outcomes of cesarean section: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015042521917N2
Enrollment
178
Registered
2015-06-09
Start date
2015-06-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean. Delivery by elective caesarean section

Interventions

Intervention 1: Intervention group: After cesarean delivery, in addition to routine medical cares, the patient's abdomen will be fastened by Paksaman Abdominal Binder produced by Iran For intervention
Treatment - Other
Intervention group: After cesarean delivery, in addition to routine medical cares, the patient's abdomen will be fastened by Paksaman Abdominal Binder produced by Iran For intervention group. For app
The control group will receive routine medical cares and medicine.

Sponsors

Vice chancellor for research, Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: First or second parity; elective cesarean section; 18 to 35 years old; having literacy; term pregnancy, singleton and without complicated pregnancy; fannenstiel incision on the skin and Kerr Incision on the uterine; hemoglobin more than 11 g/dl during Pregnancy; no history of substance abuse and smoking; no presence of placenta previa or placenta accreta, Incerta, Percreta at ultrasound; no rupture of membrane more than 6 Hours; permission of gynecologist. Exclusion criteria: Intolerance of abdominal binder by participant; no tendency to continue the study; presence of essential disease based on mother`s report; increasing the duration of surgery more than one hour; simultaneous surgery such as hysterectomy, myomectomy and tubectomy; preeclampsia or eclampsia; presence of severe bleeding or bleeding leading to hysterectomy; presence of hemorrhagic disorders or use of anticoagulant drugs such as heparin or warfarin; tissues damage during cesarean delivery.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Baseline, 6, 12, 18, 24, 48 hours and fifth day after intervention. Method of measurement: Visual Analogous Scale (VAS).;Distress. Timepoint: Baseline, 24 and 24 hours after intervention. Method of measurement: Symptom Distress Scale.;Hemoglobin and hematocrit levels. Timepoint: Baseline and 36 hours after intervention. Method of measurement: hemoglobin and hematocrit.

Secondary

MeasureTime frame
Healing of scar. Timepoint: Fifth day after cesarean section. Method of measurement: REEDA scale.;Consumed painkiller. Timepoint: 48 hours after cesarean section. Method of measurement: Calculation of number of consumed painkiller.;Satisfaction of participants. Timepoint: Fifth day after Cesarean. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSevil Hakimi

Tabriz University of Medical Sciences

Hakimis@tbzmed.ac.ir, hakimisevil@gmail.com+98 41 3479 6770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026